Acute Myeloid Leukemia

Aggressiveness of acute myeloid leukemia elucidated

Antoine Peters and colleagues at the Basel University Children's Hospital (UKBB) have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. They found ...

Jun 24, 2016
popularity5 comments 0

Potential new treatments for acute myeloid leukemia

Two separate studies yield key findings for the prevention, diagnosis, treatment and cure for acute myeloid leukemia (AML). AML is a group of heterogeneous diseases with considerable diversity in terms of genetic abnormalities. ...

Nov 25, 2013
popularity1 comments 0

New biomarkers for acute myeloid leukemia

Mariam Ibáñez, lecturer at Universidad Cardenal Herrera CEU (CEU Cardenal Herrera University, UCH-CEU) and biologist at "La Fe" Hospital in Valencia used massive sequencing techniques to identify new recurrent genes mutations ...

Dec 01, 2015
popularity2 comments 0

Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.

The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Several risk factors and chromosomal abnormalities have been identified, but the specific cause is not clear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.

AML has several subtypes; treatment and prognosis varies among subtypes. Five-year survival varies from 15–70%, and relapse rate varies from 33-78%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has resulted in the availability of tests that can predict which drug or drugs may work best for a particular patient, as well as how long that patient is likely to survive.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

The 'love hormone' may quiet tinnitus

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Science can shape healthy city planning

Previous studies have shown a correlation between the design of cities and growing epidemics of injuries and non-communicable diseases such as heart disease, diabetes and cancer. A three-part series published in The Lancet ...

Unique molecular atlas of pancreas produced

Researchers at Karolinska Institutet have managed to produce the first molecular map of the genes that are active in the various cells of the human pancreas. They have also revealed differences in genetic activity between ...

Controlling cell-fate decisions

Rafal Ciosk and his group at the FMI have identified an important link between the Notch signaling pathway and PRC2-mediated gene silencing. They showed that a fine balance between epigenetic silencing and signaling is crucial ...